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Abstract
Angiotensin-converting enzyme 2 (ACE2) is required for the cellular entry of the severe acute respiratory syndrome coronavirus
2. ACE2, via the Ang-(1-7)-Mas-R axis, is part of the antihypertensive and cardioprotective effects of the renin-angiotensin
system. We studied hospitalized COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice to
determine the outcome of COVID-19 with or without AT1 receptor (AT1R) blocker treatment. The severity of the illness and the
levels of serum cardiac biomarkers (CK, CK-BM, cTnI), as well as the inflammation markers (IL-1, IL-6, CRP), were lesser in
hypertensive COVID-19 patients treated with AT1R blockers than those treated with other antihypertensive drugs. Hypertensive
hACE2 transgenic mice, pretreated with AT1R blocker, had increased ACE2 expression and SARS-CoV-2 in the kidney and
heart, 1 day post-infection. We conclude that those hypertensive patients treated with AT1R blocker may be at higher risk for
SARS-CoV-2 infection. However, AT1R blockers had no effect on the severity of the illness but instead may have protected
COVID-19 patients from heart injury, via the ACE2-angiotensin1-7-Mas receptor axis.
Keywords Coronavirus disease 2019 . Hypertension . AT1
receptor blocker . Angiotensin converting enzyme 2
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic caused
by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) is a major public health problem. Cardiovascular diseases, including hypertension and diabetes, are the most common comorbidities that are associated with severe illness and
high case-fatality rates (CFR) in COVID-19 [1, 2]. SARSCoV-2 is a newly identified coronavirus with high genome
similarity (89%) and identity (73%) of its receptor-binding
domain (RBD) and similar ternary structure to SARS-CoV
[3–5]. Molecular modeling revealed that SARS-CoV-2 RBD
has a stronger interaction with angiotensin-converting enzyme
2 (ACE2), as cell entry receptor, than SARS-CoV [5]. ACE2
is a homologue of ACE but has physiological actions that
oppose ACE [6]. ACE cleaves angiotensin I to generate angiotensin II which binds and stimulates the AT1 receptor
(AT1R) to increase blood pressure, in part, via arterial constriction and renal sodium retention [7]. By contrast, ACE2
catalyzes the conversion of angiotensin (Ang) II into Ang1-7
which leads to vasodilatory, antiproliferative, and antiinflammatory effects via the Mas receptor. Thus, ACE2 counterbalances the effects of Ang II and exhibits antihypertensive
and cardioprotective effects in humans and several rodent
models [8].
AT1R blockers, such as losartan and olmesartan, are widely used in the therapy of hypertension. Urinary ACE2 levels
are increased in hypertensive patients treated with the AT1R
blocker (olmesartan), but not in patients treated with other
AT1R blockers, such as losartan, candesartan, valsartan, and
telminsartan [9]. However, losartan and other AT1R blockers
have been reported to increase ACE2 expression in the kidney
of spontaneously hypertensive rat and heart of mice or rat with
cardiac hypertrophy and dysfunction caused by transverse
aortic constriction or coronary artery ligation [10, 11]. It has
been suggested that angiotensin receptor 1 (AT1R) blockers
may be used to reduce the cardiac damage in SARS-CoV-2

infection [12]. Retrospective studies found that hospitalized
hypertensive patients with SARS-CoV-2 infection treated
with ACE inhibitors or AT1R blockers have a lower risk of
all-cause mortality than those treated with other drugs [13]. A
prospective cohort study also found that ACE inhibitors and
AT1R blockers are associated with a reduced progression of
COVID-19 and do not increase the risk of intensive care [14].
However, due to ACE2 is critically important in the cellular
entry of SARS and SARS-CoV-2, it is possible that hypertensive COVID-19 patients treated with drugs that increase
ACE2, e.g., ACE inhibitors and AT1R blockers, are at a
higher risk for the development and severity SARS-CoV-2
infection [15]. Indeed, hypertensive patients taking ACE inhibitors or AT1R blockers may have higher all-cause mortalities than those taking other drugs [16]. It has been suggested
that ACE2-mediated inhibition of the AT1R pathway, which
is beneficial in the treatment of hypertension, may also increase the susceptibility to pulmonary and cardiovascular disease in patients with COVID-19 [17]. Human (h) ACE2 transgenic mice, intranasally inoculated with SARS-CoV-2, develop severe pulmonary pathology with viral replication in the
lungs and intestines, at 1-day post infection (dpi) and severe
pulmonary pathology 5 dpi. There is no viral load in other
organs [18]. The disease is more severe in aged mice [19],
similar to that seen in humans [20]. The intranasal inoculation
of SARS-CoV-2 in human (h) ACE2 transgenic mice results
in 100% mortality within a few days [21]. However, the effect
of AT1R blockers in hypertensive hACE2 transgenic mice,
induced by angiotensin II and infected with SARS-CoV-2,
has not been studied. Therefore, we studied hospitalized
COVID-19 hypertensive patients and hypertensive hACE2
transgenic mice to determine whether AT1R blockers protect
or promote the development of COVID-19 [17].

Methods
See the supplementary data for details.

Results
AT1R Blockers May Protect Hypertensive COVID-19
Patients Against Inflammation and Heart Injury
One-hundred forty-six hospitalized COVID-19 patients with
hypertension were investigated, including 48 patients who
took AT1R blockers for hypertension treatment (AT1RB
group) and 98 patients who took other antihypertensive medications (Non-AT1RB group) before admission. After admission, all of them stopped taking all antihypertensive medications, including AT1R blockers, because of the concern that
the latter such medications may worsen the outcome of

J. of Cardiovasc. Trans. Res.

SARS-CoV-2 infection. The age and sex distribution, and
number of days of illness prior to admission, were similar in
the two groups (Table 1). However, the severity of the disease,
some symptoms, and some physical findings were lesser in the
AT1RB than the non-AT1RB group, which could indicate
that AT1R blockers may have reduced the severity of
SARS-CoV-2 infection in these hypertensive patients, which
was no dose-dependent effect.
We then compared the laboratory results on the admission
of the two groups. The white blood cell and neutrophil counts,
cardiac troponin levels, and interleukin-6(IL-6) levels were
lesser in the AT1RB group than those in the non-AT1RB

group (Fig. 1a). Therefore, we suggest that AT1R blockade
may decrease the inflammation in hypertensive COVID-19
patients.

Cardiac Function-Related Tests on Admission Are
Strongly Associated with the Outcome in COVID-19
Inpatients with Hypertension
In order to investigate the causes of death in all COVID-19
patients with hypertension, we analyzed the results of the laboratory tests on admission in survivors (103 patients) and nonsurvivors (43 patients) (Fig. 1b). We found that the admission

Table 1 Demographics and clinical characteristics on admission of hypertensive COVID-19 inpatients treated with AT1R blockers or non-AT1R
blockers
Variables

AT1R blockers
(n = 48)

Non-AT1R blockers
(n = 98)

P value

Age (years)
Sex
Male, n (%)
Female, n (%)
BMI (kg/m2)
Blood pressure
Systolic (mm Hg)
Diastolic (mm Hg)
Clinical severity
Mild, n (%)
Severe, n (%)
Critical, n (%)
Medical history, n (%)
Nephropathy
Cerebral infarction
Heart disease
Diabetes
Hyperlipidemia
Outcome
Recovery, n (%)
Disability, n (%)
Death, n (%)
Days of illness prior to admission, n (%)
Symptoms and physical findings
Cough, n (%)
Fever, n (%)
Runny nose, n (%)
Sputum production, n (%)
Myalgia/fatigue, n (%)
Headache, n (%)
Diarrhea, n (%)
Respiratory rate (breaths/min)
Oxygen saturation (%)
Heart rate (beats/min)

62.5 (11.55)

64.6 (9.83)

0.2472
0.7246

23 (47.9)
25 (52.1)
26.2 ± 3.1

50 (51.0)
48 (49.0)
27.5 ± 4.3

137.4 ± 17.7
84.1 ± 11.5

134.8 ± 17.4
82.7 ± 10.8

30 (62.5)
15 (31.3)
3 (6.3)

43 (43.9)
42 (42.9)
13 (13.3)

1 (2.1)
3 (6.2)
5 (10.4)
8 (16.6)
14 (29.1)

2 (2.0)
5 (5.1)
12 (12.2)
20 (20.4)
21 (21.4)

0.6439
0.5941
0.5783
0.4132
0.2291

34 (70.8)
2 (4.2)
12 (25.0)
11.0 (4.73)

65 (66.3)
2 (2.0)
31 (31.6)
12.2 (5.15)

0.5241

0.1717

33 (68.8)
41 (85.4)
0 (0)
19 (9.6)
34 (70.8)
4 (8.3)
2 (4.2)
20.0 ± 1.98
95.0 ± 4.81
97 ± 5.76

76 (78.4)
78 (79.6)
3 (3.1)
22 (22.4)
52 (53.1)
3 (3.1)
8 (8.2)
21.5 ± 1.06
92.5 ± 3.15
93 ± 9.76

0.2079
0.3944
0.5510
0.0305*
0.0403*
0.3230
0.5827
0.0077*
0.1531
0.2823

0.265
0.2754
0.1889
0.0293*

Continuous variables with normal distribution are expressed as mean ( ± SD) and compared using Student’s t-test; continuous variables with non-normal
distribution are expressed as median (IQR) and compared using Wilcoxon rank sum test; categorical variables are expressed as number (%) and
compared using χ2 test, Fisher’s exact test, or Wilcoxon rank sum test. AT1RB patients on AT1R blockers, No-AT1RB patients on antihypertensive
treatment other than AT1R blockers, BMI body mass index.
*P<0.05 vs. AT1R blockers
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Fig. 1 Laboratory test results in hypertensive COVID-19 patients with or
without AT1R blocker treatment (a) and surviving or non-surviving hypertensive COVID-19 patients (b). Continuous variables with normal distribution were expressed as mean (SD) and compared using Student’s t-test;

categorical variables were expressed as number (%) and compared using χ2
test or Fisher’s exact test. AT1RB = patients on AT1R blockers; Non-AT1RB
= patents on antihypertensive treatment other than AT1R blockers. *P<0.01
vs. AT1RB group; ***P<0.0001 vs. survivor group

serum levels of most of the cardiac function-related tests, including serum creatinine kinase (CK), lactate dehydrogenase
(LDH), cardiac troponin, and NT-proB-type natriuretic peptide (BNP), were higher in non-surviving than surviving hypertensive COVID-19 patients. The white blood cell and neutrophil counts and serum levels of procalcitonin, C-reactive
protein (CRP), IL-6, and IL-1 were also higher on admission
in non-surviving than surviving patients. By contrast, platelet
and lymphocyte counts were higher in the surviving than nonsurviving group. Therefore, we presume that cardiac

dysfunction and inflammation may be the main causes of
death in COVID-19 patients with hypertension (Fig. 1b).

Hypertensive hACE2 Mice Have an Increased Risk for
SARS-CoV-2 Infection
To assess whether high blood pressure and organ dysfunction
contribute to the increased risk for SARS-CoV-2 infection,
hACE2 transgenic mice were induced hypertensive by high
salt feeding (1% NaCl) and subcutaneous infusion of
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angiotensin II (Ang II, 500 ng/mg/day), via osmotic
minipumps, for 3 weeks before SARS-CoV-2 infection. The
lungs, kidneys, and hearts were harvested at 5 dpi (Fig. 2a).
Control hACE2 transgenic mice (black line) were normotensive group. By contrast, Ang II-infusion in hACE2
transgenic mice (blue line) caused a progressive increase
in systolic blood pressure from an initial value of 105 ±
4.1 to 178±8.3 mm Hg, 3 weeks (0d)(Fig. 2b). At 5 dpi,
no viral load was detected in the kidney, but the viral load
was higher in the lungs of hACE2 hypertensive transgenic
mice than in the normotensive hACE transgenic mice
(control)(Fig. 2c). Relative to the normotensive hACE
transgenic mice (control), the expression of ACE2 was
increased in three organs (lung, kidney, and heart) of

hypertensive hACE2 mice (Fig. 2d), which may increase
the risk for SARS-CoV-2 infection.

Fig. 2 Virus replication and representative histopathology in SARSCoV-2-infected hACE2 transgenic mice with hypertension induced by
Ang II. a Protocol for SARS-CoV-2-infection in vivo. b Systolic blood
pressure (SBP) was measured by tail-cuff plethysmography in conscious
mouse, three times at 8:30 AM. c The SARS-CoV-2 load at 5 dpi. The
SARS-CoV-2 loads in the lung and kidney of the mice were quantified by
qRT-PCR. dAngiotensin-converting enzyme 2 (ACE2) expression quantified by western blot and analyzed by ImageJ (n=3/group). Data are

presented as mean ± SD. e Morphology image (top), Massonstained(middle) and H&E-stained(bottom) sections of the lung (scale
bar is 200 μm) and heart (f) from control (normotensive hACE2 transgenic mice) and hypertensive hACE2 transgenic mice without and with
AT1R blocker treatment (5 dpi). *P<0.01 vs. control (untreated normotensive hACE2 transgenic mice), #P<0.05 vs. untreated hypertensive
hACE2 transgenic mice, Wilcoxon rank. Data are presented as mean ±
SD

AT1R Blocker Treatment Protects Hypertensive hACE2
Transgenic Mice From SARS-CoV-2-Mediated Organ
Injury
To investigate the effect of AT1R blocker on tissue injury post
SARS-CoV-2 infection in hypertensive mice, the morphology
and histopathology of the lung, heart, and kidney were evaluated at 5 dpi. There was pulmonary edema with bleeding in
hypertensive hACE2 transgenic mice, which was not detected
in the AT1R blocker-treated hypertensive hACE2 transgenic
mice (Fig. 2e). The lung morphology was similar to the non-
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SARS-CoV-2-infected normotensive hACE2 transgenic
group (control). Increased lung and myocardial fibrosis were
observed by Masson’s trichrome staining in the hypertensive
hACE2 transgenic mice that was improved by AT1R blocker
treatment. At 5 dpi, the lung pathology progressed into severe
interstitial pneumonia, with thickened alveolar septa in the
untreated hypertensive hACE2 transgenic mice with SARSCoV-2 infection (Fig. 2e). There was also some interstitial
pneumonia in the control normotensive hACE2 transgenic
mice, which is consistent with our previous study [22, 23].
MMP2, MMP9, and FN-1 expressions were upregulated in
the lung and heart (also kidney) which induced increased fibrosis and necrosis in the hypertensive hACE2 transgenic
mice (Fig. S1). Thus, AT1R blocker treatment did not aggravate the histopathological injury, but instead protected the
organs from damage caused by SARS-CoV-2 in hypertensive
hACE2 transgenic mice.

AT1R Blocker Treatment May Increase the Risk of
SARS-CoV-2 Infection in the Heart and Kidney at the
Early Period of Infection
In order to study the risk of SARS-CoV-2 infection that may be
caused by AT1R blockers, hypertensive hACE2 transgenic mice
were pretreated with the AT1R blocker, losartan (6.4ng/kg/day),
for 3 days, before the SARS-Cov-2 virus infection as above (Fig.
2a). AT1R blocker treatment (red line) attenuated the increase in
BP (145 ± 2.9 vs 178 ± 8.3 mm Hg, 0d) induced by Ang II
infusion (Fig. 2b). As shown above, the viral load at 5 dpi was
higher in the lungs of the hypertensive hACE2 transgenic mice
than control normotensive hACE2 transgenic mice; there was no
effect of AT1R blocker on the increase in the viral load (Fig. 2c).
However, there was no viral load in the kidney and heart at 5 dpi,
regardless of treatment (Fig. 2c).
We then investigated the ACE2 expression and viral replication at 1, 3, and 5 dpi in AT1R blocker-treated and AT1R
blocker-untreated (non-Ang II-infused) normotensive hACE2
transgenic mice (Fig. S2a). Western blotting showed that
ACE2 protein was increased in the lung, kidney, and heart
of the AT1R blocker-pretreated group at 1 and 3 dpi, compared with the normotensive hACE2 transgenic mice.
However, these differences were no longer observed at 5 dpi
(Fig. S2b). The viral load was similar in the lung of untreated
and AT1R blocker-treated normotensive (non-Ang II-infused)
hACE2 transgenic mice at 1, 3, and 5 dpi (Fig. S2c). However,
a relatively high viral load was observed in the kidney and
heart of AT1R blocker-pretreated normotensive mice at 1 dpi.
No viral load was detected in the kidney and heart at 3 dpi and
5 dpi (Fig. S2c) with or without AT1R blocker pretreatment in
the normotensive hACE2 transgenic mice. These results suggest that AT1R blockade may increase the risk of SARS-CoV2 infection in the heart and kidney at the early period of infection, even in the absence of hypertension.

In normotensive hACE2 transgenic mice with SARS-CoV2 infection, there were no differences in histopathological
changes in the lung, heart, and kidney at 1, 3, and 5 dpi between the AT1R blocker-untreated and pretreated group (Figs.
S3 and S4).

AT1R Blocker Treatment Decreases the Inflammatory
Reaction in Hypertensive hACE2 Transgenic Mice with
SARS-CoV-2 Infection
The protein expressions of inflammatory markers (IL-6 and
TNFα) were higher in the lung, kidney, and heart, of hypertensive hACE2 transgenic mice than normotensive hACE2
transgenic mice during SARS-CoV-2 infection. The increased
expression of inflammatory markers in hypertensive hACE2
transgenic mice was downregulated by AT1R blocker treatment (Fig. 3a and b). The mRNA expressions of two inflammatory factors (IL-6 and TNFα) were also decreased in the
lung, kidney, and heart of AT1R blocker-treated hypertensive
hACE2 transgenic mice (Fig. 3c). These results indicate that
AT1R blocker treatment decreases the inflammatory reaction
in hypertensive hACE2 transgenic mice with SARS-CoV-2
infection, which may justify its use in hypertensive patients
infected with SARS-CoV-2.

AT1R Blocker Treatment Protects Hypertensive hACE2
Transgenic Mice from Cardiac Injury by Ameliorating
Ang II/Ang1-7 Imbalance
We have found that cardiac dysfunction may be the main
cause of death in COVID-19 patients with hypertension
[24]. Epidemiological studies also indicated that COVID-19
is more severe in patients with hypertension, coronary heart
disease, and diabetes [25]. ACE2-processed Ang-(1-7)-MasR axis leads to antihypertensive and cardioprotective effects
(Fig. 3d). MasR, the Ang 1-7 receptor, was upregulated in the
lung, kidney, and heart of hypertensive hACE transgenic mice
with SARS-CoV-2 infection. The expression of MasR in the
heart was further increased in hypertensive hACE transgenic
mice treated with AT1R blocker; AT1R blocker treatment did
not change MasR expression in the lung and kidney (Fig. 3e).
Liu et al reported that Ang II levels in COVID-19 patients
correlated with viral load and organ injury [26]. We also found
increased serum Ang II levels in hypertensive hACE2 transgenic mice, which were decreased by AT1R blocker treatment
although the levels were still higher than the untreated hypertensive hACE2 transgenic mice (Fig. 3f). Serum Ang 1–7
levels were also increased in the hypertensive hACE2 transgenic mice, but AT1R blocker treatment further increased the
serum Ang 1-7 levels, the opposite of that found with Ang II
(Fig. 3f).
We also found that the serum levels of cardiac injury
markers, such as cardiac troponin I (cTnI) and creatine
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Fig. 3 Inflammation and cardiac function markers in SARS-CoV-2infected normotensive and hypertensive hACE2 transgenic mice with or
without AT1R blocker treatment. a, b Western blots of inflammation
markers, IL-6 and TNFα, analyzed by ImageJ. c mRNA expression of
inflammation markers quantified by qRT-PCR in control (normotensive
hACE2 transgenic mice) and hypertensive hACE2 transgenic mice without and with AT1R blocker treatment. d Ang II/Ang1-7 imbalance as a
key player in cardiac injury. e Western blots of cardiac MasR and

GAPDH analyzed by ImageJ; f serum levels of Ang II, Ang 1-7, cardiac
troponin I (cTnI), and creatine kinase-MB(CK-MB) in control normotensive hACE transgenic mice and hypertensive hACE2 transgenic mice
without or with AT1R blocker treatment (n=3/group, *P<0.01 vs. control,
#P<0.05 vs. untreated hypertensive hACE2 transgenic mice), Wilcoxon
rank. Immunoblots (a and e) are representatives of three independent
experiments.

kinase-myocardial band (CK-MB), were increased in SARSCoV-2-infected hypertensive hACE2 transgenic mice but normalized after AT1R blocker treatment (Fig. 3f), which is consistent with the results in our patient study (see above). These
results indicate that AT1R blocker may protect hypertensive
hACE2 mice from cardiac injury by stimulating the Ang-(17)-Mas-R axis and inhibiting the Ang II axis.

the lung, heart, intestine, and kidney, among others [3–5].
SARS-CoV-2 could exploit species-specific interferon-driven
upregulation of ACE2 to enhance infection [27]. In the current
study, we found that SARS-CoV-2 viral load in the heart and
kidney of normotensive hACE2 transgenic mice was increased by AT1R blocker treatment at 1 dpi. The highest
SARS-CoV-2 viral load was in the lung of normotensive
and hypertensive hACE2 transgenic mice, which was not affected by AT1R blocker treatment. However, the SARS-CoV2 loading did not increase the severity of injury in the lung,
heart, and kidney of normotensive hACE2 transgenic mice
with AT1R blocker pretreatment (Supplemental Fig. S3). By
contrast, in hypertensive hACE2 transgenic mice, the AT1R

Discussion
The SARS-CoV-2 uses ACE2 as a co-receptor to gain entry
inside human cells, where ACE2 is highly expressed, such as
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blocker treatment was protective against tissue injury and inflammation in the lung, kidney, and heart. ACE2 is critical for
early tissue tolerance responses to respiratory infection because elevated ACE2 may increase the ability of the host to
tolerate tissue damage [28, 29]. However, while the amount of
SARS-CoV-2 load has been reported to predict mortality [30],
an effect of AT1R blockers on the relationship between viral
load and mortality has not been reported.
In the current study, all hypertensive COVID-19 patients in 15 departments of the hospital during the local
epidemic period were investigated to study the severity of
SARS-CoV-2 infection in hypertensive COVID-19 patients with or without AT1R blocker treatment. It is very
difficult to determine if AT1R blockers affect the severity
of SARS-CoV-2 infection in human epidemiological investigation because the time of human contact with the
virus is unknown, even though one can compare the number of COVID-19 cases, with or without AT1R blocker
treatment, in the population in a specific area. Thus, with
a human survey, one can only evaluate the effect of AT1
blocker on the outcome or the severity of SARS-CoV-2
infection. All of the hypertensive COVID-19 patients in
our study stopped taking AT1R blockers after admission
to the hospital. The intake of AT1R blockers, with the
average of 11 days from the onset of illness to the hospital
admission of hypertensive COVID-19 patients, suggests
that AT1R blockers decreased the severity of SARSCoV-2 infection. Renin-angiotensin system (RAS) inhibitors have been reported to improve the clinical outcome of
COVID-19 patients with hypertension [31]. However, other investigators have reported that neither ACE inhibitors
nor AT1R blockers affected the risk of mild-to-moderate or
severe COVID-19 disease [32, 33]. In our study, the clinical severity and number of symptoms were less in the
AT1R blocker-treated than non-AT1R blocker-treated hypertensive COVID-19 patients. There may be also more
recovery and less death in COVID-19 hypertensive patients treated with AT1R blockers. The main causes of
death in COVID-19 patients were acute kidney injury,
multi-organ failure, inflammatory storm, and thromboinflammation [34–39]. Therefore, the laboratory tests on
admission could be added to the clinical presentation to
determine the effect of ACE inhibitors or AT1R blockers
on the severity of SARS-CoV-2 infection.
Acute myocarditis, with elevated blood high-sensitivity
troponin T and CK-MB levels, was reported to be associated
with the severity of COVID-19, without symptoms and signs
of interstitial pneumonia [40]. We also found that the lesser
symptoms in COVID-19 patients treated with AT1R blockers
were associated with lower serum cTnI levels in hypertensive
COVID-19 patients treated with AT1R blockers than those
not taking them. The serum cTnI and other cardiac biomarkers
were higher in non-survivors than survivors. A meta-analysis

study reported that cTnI values were higher in patients with
severe than those with milder COVID-19 [41]. Cardiac troponins, i.e., cTnI, are the biomarkers of choice in the diagnosis of
acute myocardial infarction in patients in the emergency room
[42]. In hACE transgenic mice, the serum levels of cardiac
injury markers (cTnI and CK-MB) were higher in hypertensive than normotensive hACE2 mice, which were normalized
by AT1R blocker treatment. Therefore, AT1R blockers may
decrease the severity of myocardial injury in hypertensive
COVID-19 patients.
The protective effect of AT1R blockers in hypertensive
COVID-19 patients has been reviewed recently [12, 43–45].
As aforementioned, SARS-CoV-2 uses ACE2 to enter the cell
[5, 17, 46]. An imbalance in the RAS that favors the Ang II/
AT1R axis increases the likelihood of developing severe
COVID-19 [46–49]. ACE2 converts Ang II to angiotensin
1-7 (Ang1-7). An increase in ACE2 expression may protect
the organs from the virus injury by increasing Ang-(1-7) and
decreasing Ang II levels [49, 50]. Ang1-7 binds to the Mas
receptor (MasR) that mediates anti-inflammatory, antioxidative, and vasodilatory effects [49, 50]. In hypertensive hACE2
transgenic mice, serum Ang1-7 levels and cardiac MasR expressions were increased, but serum Ang II levels were decreased in AT1R blocker group. We also found that serum
Ang-(1-7) levels at 1 dpi were increased in SARS-CoV-2infected hACE2 transgenic mice with AT1R blocker pretreatment compared with AT1R blocker-untreated mice (data not
shown). Therefore, we suggest that AT1R blocker may protect
hypertensive COVID-19 patients from heart injury caused by
SARS-CoV-2 infection via the ACE2-Ang-(1-7)-Mas-R axis
(Scheme 1).

Perspectives
The clinical severity of SARS-CoV-2 infection was lesser in
AT1R blocker-treated than AT1R blocker-untreated hypertensive patients. AT1R blockers were protective against organ
injury in hypertensive hACE2 transgenic mice. AT1R blocker
treatment was also associated with a decrease in inflammatory
markers (TNFα and IL-6). Serum cTnI may be a biomarker
that predicts the progression of COVID-19. Although AT1R
blockers may increase the risk of SARS-CoV-2 infection in
the heart and kidney at the early period of infection, they may
be beneficial in the treatment of hypertensive patients with
SARS-CoV-2 infection. However, studies in large populations are still needed to evaluate the effect and mechanism
of AT1R blockade on the severity and outcome of COVID19 patients with cardiovascular diseases. More studies are also
needed to determine the mechanism of the beneficial effect of
AT1R blockers, in general, or specific AT1R blockers, in
particular, in hypertensive animal models.

J. of Cardiovasc. Trans. Res.
Scheme 1 Processing and
function scheme of AT1R blocker
action in hypertensive COVID-19
patients. Angiotensin II type I receptor (AT1R) blocker increases
angiotensin-converting enzyme 2
(ACE2) expression. The increased ACE2 expression may
potentiate the risk of SARS-CoV2 infection, which results in cardiac injury. However, the increase
in ACE2 converts more angiotensin (Ang) II to Ang-(1-7),
which binds to the Mas receptor
(Mas-R) to protect the heart from
injury caused by SARS-CoV-2
infection. AT1R blockade also
stimulates plasm angiotensin II
levels but decreases renal angiotensin II levels [51]

Limitations
Our study has some limitations. First, this study had to be
done in the animal biosafety level 3 (ABSL3) facility, where
ultrasound and telemetric measurement of blood pressure are
not available. Therefore, we cannot provide cardiac ultrasound data and only tested several serum markers to represent
cardiac function. Second, although our study provides additional evidence that ACE2/Ang-1-7/MasR is the protective
arm of the RAS, which may countervail the deleterious effects
of Ang II in several organs, the mechanisms were not determined. Finally, these studies in Wuhan Chinese may not be
generalizable to other racial/ethnic groups.
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